Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jun 24, 2014; 4(2): 122-132
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.122
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.122
Multiple indications for everolimus after liver transplantation in current clinical practice
Itxarone Bilbao, Cristina Dopazo, Jose Lazaro, Mireia Caralt, Gonzalo Sapisochin, Ramon Charco, Hepatobiliopancreatic Surgery and Liver Transplant Unit of the Department of General Surgery, Hospital Vall Hebrón, Universidad Autónoma Barcelona, 08035 Barcelona, Spain
Lluis Castells, Hepatology Unit of the Department of Internal Medicine, Hospital Vall Hebrón, Universidad Autónoma Barcelona, 08035 Barcelona, Spain
Itxarone Bilbao, Lluis Castells, Ramon Charco, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD o Ciberehd), Hospital Vall d´Hebron, 08035 Barcelona, Spain
Author contributions: Bilbao I, Castells L and Charco R contributed to study design and data analysis; Dopazo C, Lazaro J, Caralt M and Sapisochin G contributed to data collection; Bilbao I contributed to drafting of manuscript.
Correspondence to: Itxarone Bilbao, MD, PhD, Hepatobiliopancreatic Surgery and Liver Transplant Unit of the Department of General Surgery, Hospital Vall Hebrón, Universidad Autónoma Barcelona, Paseo Vall d´Hebron, 119-129, 08035 Barcelona, Spain. ibilbao@vhebron.net
Telephone: +34-93-2746113 Fax: +34-93-2746112
Received: February 23, 2014
Revised: April 14, 2014
Accepted: May 29, 2014
Published online: June 24, 2014
Revised: April 14, 2014
Accepted: May 29, 2014
Published online: June 24, 2014
Core Tip
Core tip: Everolimus has a completely different mechanism of action to that of current basal calcineurine inhibitors used worldwide in liver transplantation. This immunosuppressant has a good profile for patients with pre- and post transplant renal dysfunction, one of the main concerns nowadays. It has also a promising role in cancer patients which is common in liver transplantation, either as an underlying disease (hepatocarcinoma in cirrhosis), or as de novo developing tumors. We present our off-protocol experience with partial/total and early/late conversion to everolimus, highlighting its efficacy and safety in fitting with the different emerging scenarios after liver transplantation.